Modeled after advanced computers used in industrial applications, such as automotives, Proteus Biomedical hopes to bring what it calls pervasive computing to treat chronic conditions such as chronic heart failure and, later on, others. The company's approach combines device and drug therapy in an innovative kind of combination products; in the process, says Proteus, it will define not just a new category of medical products but also shape a new competitive landscape.
by David Cassak
For nearly a decade, one of the hottest topics in medical devices has been drug/device convergence: combining in a single...
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.
Ovid Therapeutics' president and COO Meg Alexander is leading the company’s strategic pivot toward innovative neurological treatments, potentially creating a new class of medicines for rare neurological disorders.
Thijs Spoor's bet on lead-212 is paying off as Perspective Therapeutics advances three clinical programs with promising early efficacy signals and a comprehensive manufacturing strategy.
